Fas ligand-deficient gld mice are more susceptible to graft-versus-host- disease

Transplantation

Volumn 70, Issue 1, 2000, Pages 184-191

  Van Den Brink, Marcel R M ^a,b,e   Moore, Ellen ^a   Horndasch, Kirsten J ^a   Crawford, James M ^c   Murphy, George F ^d   Burakoff, Steven J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HLA MATCHING; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE SUSCEPTIBILITY; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MONOCYTES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034661624     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease [see comments]. N Engl J Med 1991; 324 (10): 667.
2. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64 (4): 553.
3. Nagata S. Apoptosis by death factor. Cell 1997; 88 (3): 355.
4. Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148 (4): 1274.
5. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154 (8): 3806.
6. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184 (2): 429.
7. De Maria R, Testi R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol Today 1998; 19 (3): 121.
8. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76 (6): 969.
9. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269.
10. Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178 (6): 2231.
11. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 1998; 187 (1): 123.
12. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding [see comments]. Nat Med 1998; 4 (1): 31.
13. Strasser A, O'Connor L. Fas ligand - caught between Scylla and Charybdis. Nat Med 1998; 4 (1): 21.
14. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270 (5239): 1189.
15. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158 (9): 4122.
16. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection [see comments] [published erratum appears in Nature 1998; 394 (6689): 133], Nature 1995; 377 (6550): 630.
17. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274 (5291): 1363.
18. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184 (3): 1075.
19. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273 (5271): 109.
20. Zhang HG, Liu D, Heike Y, et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol 1998; 16 (11): 1045.
21. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99 (6): 1173.
22. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94 (8): 3943.
23. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275 (5302): 960.
24. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89 (1): 17.
25. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3 (7): 738.
26. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4 (4): 415.
27. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89 (7): 1067.
28. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183 (2): 657.
29. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996; 157 (12): 5387.
30. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183 (6): 2645.
31. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perform function. Proc Natl Acad Sci USA 1997; 94 (4): 1366.
32. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100 (4): 904.
33. Perkins DL, Michaelson J, Marshak-Rothstein A. The 1pr gene is associated with resistance to engraftment by lymphoid but not erythroid stem cells from normal mice. J Immunol 1987; 138 (2): 466.
34. Theofilopoulos AN, Balderas RS, Gozes Y, et al. Association of lpr gene with graft-vs.-host disease-like syndrome. J Exp Med 1985; 162 (1): 1.
35. Mori T, Nishimura T, Ikeda Y, Hotta T, Yagita H, Ando K. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelo-suppression. Blood 1998; 92 (1): 101.
36. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91 (11): 4051.
37. Albanese J, Dainiak N. Ionizing radiation alters Fas antigen ligand at the cell surface and on exfoliated plasma membrane-derived vesicles: implications for apoptosis and intercellular signaling. Radiat Res 2000; 153 (1): 49.
38. Drouet M, Mathieu J, Grenier N, Multon E, Sotto JJ, Herodin F. The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, FLT-3 ligand, TPO, and IL-3 in combination resulted in CD34+ cell proliferation and differentiation. Stem Cells 1999; 17 (5): 273.
39. Belka C, Marini P, Lepple-Wienhues A, et al. The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene 1999; 18 (35): 4983.
40. Sheard MA, Krammer PH, Zaloudik J Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer 1999; 80 (11): 1689.
41. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci USA 1997; 94 (11): 5750.
42. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma- irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 1998; 5 (10): 884.
43. Belka C, Marini P, Budach W, et al. Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiat Res 1998; 149 (6): 588.
44. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104 (1): 49.
45. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol 1998; 161 (6): 2848.
46. Hiroyasu S, Shiraishi M, Koji T, et al. Analysis of Fas system in pulmonary injury of graft-versus-host disease after rat intestinal transplantation. Transplantation 1999; 68 (7): 933.
47. Shiraishi M, Hiroyasu S, Oshiro T, et al. Early detection of apoptosis and fas ligand expression in hepatic graft-versus-host disease after rat small bowel transplantation. J Surg Res 1999; 86 (1): 136.
48. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88 (8): 3230.
49. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol 1986; 86 (4): 371.
50. Blatter DD, Crawford JM, Ferrara JL. Nuclear magnetic resonance of hepatic graft-versus-host disease in mice. Transplantation 1990; 50 (6): 1011.
51. Korngold R, Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987; 165 (6): 1552.
52. Korngold R, Leighton C, Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 1994; 58 (3): 278.
53. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90 (8): 3204.
54. van den Brink MRM, Moore E, Ferrara JLM, Burakoff SJ. Graft-versus-host disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation 2000; 69: 446.
55. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol 1994; 152 (4): 1609.
56. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-host disease. New York: Marcel Dekker, 1997: 257.
57. Piguet PF, Grau-GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166 (5): 1280.
58. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79 (12): 3362.